Drug Discovery World

AUGUST 17, 2022

The funding, which is being provided under the EIB’s venture debt instrument, will help Ryvu finance its development pipeline of new cancer treatments from discovery through to clinical trials. EIB Vice-President?Teresa Teresa Czerwin?ska?said:

Small Molecule 130

Small Molecule Clinical Trials Clinical Development Treatment 130

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. About Sosei Heptares.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. This latest development follows the US Food and Drug Administration (FDA) giving clearance for QN-302 in July 2023 to proceed to this initial clinical trial stage.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio intend to continue a Phase IIb clinical trial in 2024 in the United States, Europe, and Japan. Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD. Under the amended agreement, VantAI will be eligible to receive up to $1.25

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Broad Institute

NOVEMBER 2, 2023

“Bayer’s established collaboration with the Broad Institute has already resulted in three clinical oncology candidates over the past decade. We look forward to continuing our work with renowned Broad scientists to advance additional innovative cancer targets into clinical development.”

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Target Review

OCTOBER 11, 2023

Symptoms were reversed in mouse models and a clinical trial is planned for later this year. 5 This drug candidate is progressing towards the clinic, with phase 1 trials due to start within 18 months. Autophagy boosters, in contrast, are conventional small molecule drugs.

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

LifeSciVC

JANUARY 16, 2024

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Small molecule GLP1s? Additional trials (e.g.,

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Target Review

JULY 18, 2024

Beyond the standard tumour-informed assay, we collaborated with Natera to create a more sensitive tumour-informed test using its Signatera molecular residual disease testing technology for research use in our AMPLIFY-201 clinical trial. In later stage trials, additional clinical trial designs are made possible by liquid biopsy.

Drug Development 59

Drug Development Clinical Trials Drugs Small Molecule 59

The Pharma Data

JANUARY 13, 2021

PITTSBURGH–( BUSINESS WIRE )– Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The trial was conducted at 28 U.S. 14, 2021 11:00 UTC. study centers. ABOUT ORAL DEXPRAMIPEXOLE.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

Sygnature Discovery

NOVEMBER 29, 2023

A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered to patients for the first time in a Phase 1a clinical trial. This latest development follows the US Food and Drug Administration (FDA) giving clearance for QN-302 in July 2023 to proceed to this initial clinical trial stage.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

Advarra

FEBRUARY 24, 2023

In most cases, the results you are really looking for and trying to prove in a trial can be complex. One area receiving increased focus from the Food and Drug Administration (FDA) are trial designs incorporating multiple endpoints to support efficacy. All key questions to consider and address before the therapy even leaves the lab.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

Drug Discovery World

JANUARY 4, 2024

ANX1502 is a first-in-kind oral, selective small molecule inhibitor that targets the active form of C1s responsible for propagating classical pathway activation in association with C1q. No serious adverse events were reported, and there were no significant clinical or lab findings.

Small Molecule 130

Small Molecule Pharmacokinetics Clinical Development Disease 130

The Pharma Data

MAY 15, 2023

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Target Review

MAY 1, 2024

The advent of monoclonal antibodies paired with improvements in each ADC design component has led to the approval of 11 ADCs with more than 180 ADCs currently in clinical development. Notably, novel linker-payload technologies applied to the same target have provided significant improvements over previous generation ADCs.

FDA Approval 69

FDA Approval Drugs Organic Chemistry Small Molecule 69

The Pharma Data

SEPTEMBER 29, 2020

It is a synthetic small molecule that would be self-administered via nasal spray, taken once or twice a week for the prevention of COVID-19. from Australian investors to progress the INNA-051 clinical development programme. So far, Ena has raised AU$11.7m We’ve been amazed with just how effective our treatment has been.

Small Molecule 52

Small Molecule Immune Response Virus Treatment 52

The Pharma Data

OCTOBER 19, 2020

The appointments of Maarten and Teun come at an essential time for AM-Pharma as we finalize all preparations to move into the last stage of clinical development for our lead program,” said Erik van den Berg , Chief Executive Officer at AM-Pharma. Dr. Kraan joins AM-Pharma from Pierre Fabre S.A., Kenilworth, N.J., pharma.com.

Trials 40

Trials Small Molecule Cell Biology Pharmaceutical Companies 40

Drug Target Review

JULY 18, 2023

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. Cavlan explains that “they are brilliant at developing and bringing new drugs to market.”

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

The Pharma Data

OCTOBER 18, 2020

Dr. Berk, commented “I am excited to join the Board of Inflection Biosciences as it advances its novel PIM/PI3K inhibitor, IBL-202, towards clinical development for unmet needs in B-cell malignancies and other cancers.”. Dr. Berk most recently has served as a consultant to several companies developing oncology therapies.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

OCTOBER 27, 2020

Mirati is advancing a novel pipeline to treat large patient populations across multiple programs and tumor types, including two programs, adagrasib and sitravatinib, in registration-enabling studies to treat non-small cell lung cancer (NSCLC). Forward-Looking Statements.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

DECEMBER 10, 2020

“We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). About LX9211.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Drug Discovery World

FEBRUARY 22, 2024

The lead programme is focused on identifying small molecule activators of TRPML1 for the treatment of CNS degenerative disorders, as well as degenerative peripheral indications. The post Informatics helps virtual biotech bring compound to clinical trial appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Trials Small Molecule Compound Screening 130

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

MARCH 13, 2022

In particular, we’re hopeful that we can accelerate clinical development of etrasimod successfully to have a positive impact on those living with these debilitating diseases.”. Arena has previously indicated that it expected the results of the Phase 3 ELEVATE-UC trial of etrasimod in ulcerative colitis during the first quarter of 2022.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Biosimilars Disease 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

DECEMBER 10, 2020

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicinehas published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. Chief Medical Officer and Co-founder of BioNTech. There were no COVID-19 related deaths.

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

Precision for Medicine

JUNE 26, 2023

“Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines,” said John Khoury, Executive Vice President at Project Farma.

Science 40

Science Small Molecule Clinical Research Engineering 40

The Pharma Data

APRIL 11, 2023

Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients. Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

The Pharma Data

JANUARY 10, 2021

(Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, today announced it has submitted an Investigational New Drug (IND) application with the U.S.

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

JANUARY 19, 2021

TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor.

Small Molecule 52

Small Molecule Laboratories Trials Immune Response 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

OCTOBER 27, 2020

Foghorn is anticipating filing an IND later this year for its lead candidate to begin a Phase I trial for the treatment of uveal melanoma, a cancer of the eye. . Sirnaomics is the only biopharma conducting R&D and clinical development in the field of RNAi therapeutics in both the U.S. Scorpion Therapeutics .

Small Molecule 52

Small Molecule Immune Response Pharmacokinetics Clinical Development 52

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

JANUARY 11, 2021

MediciNova intends to use the proceeds received from the private placement primarily for the following three programs: 1) To initiate a new clinical trial of MN-166 (ibudilast) for glioblastoma, which could be a pivotal trial. About MediciNova. MediciNova, Inc.

Clinical Trials 52

Clinical Trials Trials Small Molecule Vaccine 52

The Pharma Data

JANUARY 3, 2021

Based on the strong scientific rationale for telaglenastat in KEAP1/NRF2 mutant non-small cell lung cancer patients, and the safety profile observed in CANTATA, we remain dedicated to advancing our randomized KEAPSAKE trial.”. The CANTATA trial enrolled 444 patients at multiple centers globally. SOUTH SAN FRANCISCO, Calif.,

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

JANUARY 18, 2021

RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. for the treatment of post-herpetic neuralgia. for the treatment of post-herpetic neuralgia.

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40